European Urology Focus

Slides:



Advertisements
Similar presentations
Diana Cardona-Grau, Igor Sorokin, Gabriel Leinwand, Charles Welliver 
Advertisements

European Urology Focus
Volume 61, Issue 5, Pages (May 2012)
Volume 68, Issue 6, Pages (December 2015)
Early Detection of Prostate Cancer in 2007
Volume 56, Issue 5, Pages (November 2009)
Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands  Anouk Jochems, Maartje G. Schouwenburg,
Volume 55, Issue 1, Pages 1-8 (January 2009)
Economic Value of the Transurethral Resection in Saline System for Treatment of Benign Prostatic Hyperplasia in England and Wales: Systematic Review,
European Urology Focus
Volume 57, Issue 1, Pages (January 2010)
Volume 50, Issue 1, Pages (July 2006)
Volume 52, Issue 1, Pages (July 2007)
Volume 51, Issue 2, Pages (February 2007)
Volume 60, Issue 2, Pages (August 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database  Alexandros Tsikkinis, Nikola.
European Urology Focus
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
Prostate Cancer 2008: Challenges in Diagnosis and Management
Volume 70, Issue 1, Pages (July 2016)
Volume 68, Issue 4, Pages (October 2015)
Volume 73, Issue 6, Pages (June 2018)
Volume 61, Issue 2, Pages (February 2012)
Prostate Cancer Epidemic in Sight?
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology  Philipp.
Volume 70, Issue 5, Pages (November 2016)
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
Volume 68, Issue 4, Pages (October 2015)
Volume 63, Issue 2, Pages (February 2013)
Volume 53, Issue 2, Pages (February 2008)
Volume 74, Issue 1, Pages (July 2018)
Volume 70, Issue 4, Pages (October 2016)
Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Volume 66, Issue 6, Pages (December 2014)
Laurent Boccon-Gibod  European Urology Supplements 
Luis Martínez-Piñeiro  European Urology Supplements 
Prostate Cancer Epidemic in Sight?
Volume 65, Issue 2, Pages (February 2014)
Volume 61, Issue 5, Pages (May 2012)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 66, Issue 2, Pages (August 2014)
Volume 63, Issue 3, Pages (March 2013)
Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review  Sven van.
Volume 71, Issue 1, Pages (January 2017)
Volume 68, Issue 6, Pages (December 2015)
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 71, Issue 2, Pages (February 2017)
Volume 48, Issue 6, Pages (December 2005)
Volume 64, Issue 4, Pages (October 2013)
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Volume 59, Issue 4, Pages (April 2011)
Volume 70, Issue 1, Pages (July 2016)
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Volume 68, Issue 5, Pages (November 2015)
New Trends in Managing the Prostate Cancer Patient
The Cost to Medicare of Bladder Cancer Care
Prostate Cancer 2008: Challenges in Diagnosis and Management
Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.
European Urology Oncology
Volume 52, Issue 6, Pages (December 2007)
Volume 51, Issue 2, Pages (February 2007)
Cost-effectiveness of endovascular revascularization compared to supervised hospital- based exercise training in patients with intermittent claudication:
Volume 54, Issue 1, Pages (July 2008)
Presentation transcript:

European Urology Focus Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry  Hans M. Westgeest, Carin A. Uyl-de Groot, Reindert J.A. van Moorselaar, Ronald de Wit, Alphonsus C.M. van den Bergh, Jules L.L.M. Coenen, Harrie P. Beerlage, Mathijs P. Hendriks, Monique M.E.M. Bos, Pieter van den Berg, Agnes J. van de Wouw, Roan Spermon, Michiel O. Boerma, Maud M. Geenen, Lidwine W. Tick, Marco B. Polee, Haiko J. Bloemendal, Igor Cordia, Frank P.J. Peters, Aad I. de Vos, Joan van den Bosch, Alphonsus J.M. van den Eertwegh, Winald R. Gerritsen  European Urology Focus  DOI: 10.1016/j.euf.2016.09.008 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Flow diagram of the study population. CRPC=castration-resistant prostate cancer. European Urology Focus DOI: (10.1016/j.euf.2016.09.008) Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 2 Unadjusted overall survival from castration-resistant prostate cancer (CRPC) diagnosis; median overall survival standard care versus trial subgroup 24 months versus 35 months (p<0.001). European Urology Focus DOI: (10.1016/j.euf.2016.09.008) Copyright © 2016 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.